Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeMEDTRONIC plcLate Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients

Late Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the Global SYMPLICITY Registry (GSR) indicating that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System was associated with clinically significant and sustained blood pressure reductions in a real-world hypertensive patient population through three years.

Results from the prospective, single-arm, global, observational study are being presented as a Late-Breaking Clinical Trial session at the 2021 EuroPCR Annual Meeting.

The study analyzed nearly 3,000 patients with uncontrolled hypertension (HTN) and other comorbidities typical in HTN patients (chronic kidney disease, diabetes). Patients were treated with the Symplicity Renal Denervation System utilizing the single electrode Symplicity Catheter or the Symplicity Spyral Multi-Electrode Catheter, and their outcomes were analyzed up to three years post procedure. RDN with the radiofrequency based Symplicity Renal Denervation System is a minimally invasive procedure intended to regulate overactivity of nerves that lead to and from the kidney, which play an important role in blood pressure control.

The GSR study results demonstrated the Symplicity Renal Denervation System led to significant and clinically meaningful reductions in blood pressure that were sustained out to three years post-procedure. Patients experienced a mean reduction of 16.7 mmHg office systolic blood pressure (OSBP) at three years compared to baseline.

Investigators also evaluated the benefit of RDN within various patient subgroups using a clinical composite endpoint; a retrospective analysis comprised of both OSBP, 24-hour ambulatory blood pressure (ABPM) and medication burden. They found a consistent benefit of RDN in patients with versus without diabetes, chronic kidney disease, or patients who were 65 years and above. The similar clinical composite endpoint was used in a recent EuroIntervention publication that showed patients were nearly three times more likely to benefit from RDN compared to remaining on a regime of anti-hypertensive medications alone (Win Ratio = 2.78, p<0.001).1

“As we continue to expand our clinical data around renal denervation for uncontrolled hypertension management, we wanted to broaden our understanding of the long-term benefits for our patients who suffer from multiple chronic conditions and are typically prescribed multiple medications,” said Felix Mahfoud, M.D., cardiologist at Saarland University Hospital in Homburg, Germany and principal investigator in the study. “With this new analysis, we can now help patients continue to see the real-world benefits of renal denervation.”

EuroPCR: New Analysis on Estimated Risk Reduction from Symplicity RDN System
In addition to the Late Breaking Clinical Trial results at EuroPCR, investigators also reported a new analysis estimating the reduction in clinical events in patients treated with the Symplicity RDN system. The analysis used the clinical events observed at three years in the Global SYMPLICITY Registry and put these in perspective with a modeled control. The results showed a 26% relative risk reduction in major cardiovascular events (MACE) over three years for the full study cohort treated with RDN, and a 34% reduction for patients suffering from resistant hypertension over the same timeframe.

Medtronic Expands RDN Real-World Data Collection with the New GSR-DEFINE Study
Building on the success of GSR and continuing its commitment to providing real-world evidence for the Symplicity Spyral Renal Denervation System, Medtronic also announced today launch of the GSR-DEFINE Study. This new phase of patient data collection aims to enroll an additional 2,000 patients suffering from uncontrolled hypertension, who will be treated with the Medtronic Symplicity Spyral Multi-Electrode Renal Denervation Catheter. The study will collect data for a subgroup of patients out to five years.

“Medtronic’s commitment to creating a minimally invasive solution to treat patients with uncontrolled high blood pressure is evident through our growing body of clinical evidence as part of our Symplicity Global Clinical Program,” said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business unit, which is part of the Cardiovascular Portfolio at Medtronic. “The data presented today at EuroPCR not only add to our understanding of RDN’s durability as a tool for hypertension treatment, but it also continues to propel Medtronic as a leader in this space.”

About the Medtronic Symplicity Spyral Clinical Program
Along with the GSR and GSR-DEFINE studies, the Medtronic Symplicity Global Clinical Program also includes the SPYRAL HTN-OFF MED PIVOTAL and SPYRAL HTN-ON MED trials, both prospectively powered, randomized, sham-controlled studies evaluating patients with uncontrolled blood pressure in the absence and presence of prescribed anti-hypertensive medications respectively.2

Approved for commercial use in more than 60 countries around the world, the Symplicity Spyral Renal Denervation System is limited to investigational use in the U.S., Japan and Canada.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy